Publications Archives

← ALL PUBLICATIONS

Publications

Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

wmm2023-04-10T20:22:16-07:00March 23rd, 2023|2023 Publications, Featured Publications, Publications|

Minimal/Measurable Residual Disease (MRD) Monitoring in Patients with Lymphoid Neoplasms by High-Throughput Sequencing of the T-Cell Receptor

wmm2023-04-10T20:24:04-07:00March 2nd, 2023|2023 Publications, Featured Publications, Publications|

Comparing Data Generated Using Multiparametric Flow Cytometry, Capillary Electrophoresis, and Next-Generation Sequencing in a Cohort of B-Cell Lymphoproliferative Disorder Samples

wmm2022-12-29T21:22:21-08:00November 15th, 2022|2022 Publications, Featured Publications, Publications|

LymphoTrack Is Equally Sensitive as PCR GeneScan and Sanger Sequencing for Detection of Clonal Rearrangements in ALL Patients

wmm2022-12-29T21:19:31-08:00June 4th, 2022|2022 Publications, Featured Publications, Publications|

Immunoglobulin Heavy Chain High-Throughput Sequencing in Pediatric B-Precursor Acute Lymphoblastic Leukemia: Is the Clonality of the Disease at Diagnosis Related to Its Prognosis?

wmm2023-01-08T18:20:36-08:00May 30th, 2022|2022 Publications, Featured Publications, Publications|

Real-world data on prognostic value of measurable residual disease assessment by fragment analysis or next-generation sequencing in multiple myeloma

Invivoscribe Marketing2022-09-07T22:22:23-07:00May 3rd, 2022|2022 Publications, Featured Publications, Publications|

Ig Gene Clonality Analysis Using Next-Generation Sequencing for Improved Minimal Residual Disease Detection with Significant Prognostic Value in Multiple Myeloma Patients

wmm2022-01-06T05:38:03-08:00January 4th, 2022|2022 Publications, Featured Publications, Publications|

NGS Analysis of Clonality and Minimal Residual Disease in a Patient with Concurrent Richter’s Transformation and CLL/SLL

wmm2022-01-08T23:37:03-08:00December 28th, 2021|2021 Publications, Publications|

Plan for a Successful International Drug Approval with Early Development of the Accompanying CDx

wmm2022-01-04T04:43:02-08:00December 8th, 2021|2021 Publications, Publications|

Machine Learning Algorithms Accelerate Throughput of a Flow – Sequencing Cell Based Assay for an Acute Myeloid Leukemia (AML) Therapeutic Discovery Platform

wmm2022-01-30T21:35:17-08:00November 5th, 2021|2021 Publications, Publications|

Immunoglobulin gene rearrangement in Koreans with multiple myeloma: Clonality assessment and repertoire analysis using next-generation sequencing

Invivoscribe Marketing2022-09-07T22:31:04-07:00June 24th, 2021|2021 Publications, Featured Publications, Publications|

Feasibility of cell-free DNA collection and clonal immunoglobulin sequencing in South African patients with HIV-associated lymphoma

wmm2023-01-10T16:48:18-08:00April 28th, 2021|2022 Publications, Featured Publications, Publications|

Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

Invivoscribe Marketing2021-04-27T17:17:21-07:00April 20th, 2021|2021 Publications, Publications|

Validation and interpretation of IGH and TCR clonality testing by Ion Torrent S5 NGS for diagnosis and disease monitoring in B and T cell cancers

Invivoscribe Marketing2021-02-11T19:51:54-08:00November 25th, 2020|2020 Publications, Publications|

Classification of intestinal T‐cell receptor repertoires using machine learning methods can identify patients with coeliac disease regardless of dietary gluten status

Invivoscribe Marketing2021-02-11T19:57:34-08:00November 22nd, 2020|2020 Publications, Publications|

Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Invivoscribe Marketing2021-02-17T18:10:07-08:00November 17th, 2020|2020 Publications, Featured Publications, Publications|

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

Invivoscribe Marketing2021-02-11T20:05:42-08:00October 30th, 2020|2020 Publications, Publications|

Plasticity of the human IgM repertoire in response to long‐term spaceflight

Invivoscribe Marketing2021-02-11T20:09:45-08:00October 13th, 2020|2020 Publications, Featured Publications, Publications|

Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy

Invivoscribe Marketing2021-02-11T20:11:02-08:00October 8th, 2020|2020 Publications, Publications|

Genetic evolution of in situ follicular neoplasia to aggressive B-cell lymphoma of germinal center subtype

Invivoscribe Marketing2021-02-11T20:13:51-08:00August 27th, 2020|2020 Publications, Publications|

Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment

Invivoscribe Marketing2021-02-11T20:26:38-08:00July 22nd, 2020|2020 Publications, Publications|

Evaluation of the polymerase chain reaction–based T-cell receptor β clonality test in the diagnosis of early mycosis fungoides

Invivoscribe Marketing2021-02-11T21:43:52-08:00June 8th, 2020|2020 Publications, Publications|

Evaluation of Somatic Hypermutation Status in Chronic Lymphocytic Leukemia (CLL) in the Era of Next Generation Sequencing

Invivoscribe Marketing2021-02-11T21:47:46-08:00May 19th, 2020|2020 Publications, Publications|

Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment

Invivoscribe Marketing2021-02-15T19:48:14-08:00May 6th, 2020|2020 Publications, Publications|

Upgraded Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma

Invivoscribe Marketing2021-02-11T21:50:38-08:00May 1st, 2020|2020 Publications, Publications|

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

A proven strategy to accelerate drug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021 Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020 Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

Lymphoma

Myeloma

Browse our comprehensive menu of product & testing services.

Title

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing

April 20th, 2021
Validation of a Next-Generation Sequencing-based T-Cell Receptor Gamma Gene Rearrangement Diagnostic Assay: Transitioning from Capillary Electrophoresis to Next-Generation Sequencing

November 17th, 2020
Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing